Indication
Peripheral T-Cell Lymphoma Recurrent
1 clinical trial
1 product
Product
LB1901Clinical trial
A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01